Evidence map›Paper›PMID 34112843›Full record

ArticleScientific reports2021

HGK promotes metastatic dissemination in prostate cancer.

Sara Garcia-Garcia, Maria Rodrigo-Faus, Noelia Fonseca, Sara Manzano, Balázs Győrffy, Alberto Ocaña, Paloma Bragado, Almudena Porras, Alvaro Gutierrez-Uzquiza

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sara Garcia-Garcia *Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain.
Maria Rodrigo-Faus *Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain.
Noelia FonsecaDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain.
Sara ManzanoDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain.
Balázs GyőrffyDepartment of Bioinformatics and 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Alberto OcañaInstituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Paloma BragadoDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain.
Almudena PorrasDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain.
Alvaro Gutierrez-UzquizaDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia , Universidad Complutense de Madrid, Ciudad Universitaria , Madrid, Spain. alguuz@ucm.es.
Universidad Complutense de Madrid · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis is the process of cancer cell dissemination from primary tumors to different organs being the bone the preferred site for metastatic homing of prostate cancer (PCa) cells. Prostate tumorigenesis is a multi-stage process that ultimately tends to advance to become metastatic PCa. Once PCa patients develop skeletal metastases, they eventually succumb to the disease. Therefore, it is imperative to identify essential molecular drivers of this process to develop new therapeutic alternatives for the treatment of this devastating disease. Here, we have identified MAP4K4 as a relevant gene for metastasis in PCa. Our work shows that genetic deletion of MAP4K4 or pharmacological inhibition of its encoded kinase, HGK, inhibits metastatic PCa cells migration and clonogenic properties. Hence, MAP4K4 might promote metastasis and tumor growth. Mechanistically, our results indicate that HGK depleted cells exhibit profound differences in F-actin organization, increasing cell spreading and focal adhesion stability. Additionally, HGK depleted cells fails to respond to TNF-α stimulation and chemoattractant action. Moreover, here we show that HGK upregulation in PCa samples from TCGA and other databases correlates with a poor prognosis of the disease. Hence, we suggest that it could be used as prognostic biomarker to predict the appearance of an aggressive phenotype of PCa tumors and ultimately, the appearance of metastasis. In summary, our results highlight an essential role for HGK in the dissemination of PCa cells and its potential use as prognostic biomarker.

Indexed as

ActinsBiomarkers, TumorCell AdhesionCell CycleCell Line, TumorCell MovementCell Transformation, NeoplasticGene ExpressionGene SilencingHumansIntracellular Signaling Peptides and ProteinsMaleModels, BiologicalNeoplasm MetastasisNeoplasm StagingPrognosisActinsBiomarkers, TumorIntracellular Signaling Peptides and ProteinsMAP4K4 protein, humanProtein Serine-Threonine KinasesTumor Necrosis Factor-alpha

Identifiers

PMID34112843
PMCPMC8192525
OpenAlexW3166795112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.